ClinicalTrials.gg
Not yet recruitingNCT07330310Updated Jan 14, 2026

A Phase 3 Trial of JKN2401 Injection in COPD

A Phase 3 interventional study of JKN2401 Injection and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Joincare Pharmaceutical Group Industry Co., Ltd. Not yet recruiting. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by Joincare Pharmaceutical Group Industry Co., Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
888
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

02

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • JKN2401
03

In context

Pulmonary Disease, Chronic Obstructive

5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

This study's planned enrollment of 888 is above the median of 62 across 3,845 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Joincare Pharmaceutical Group Industry Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written ; able and willing to comply with study procedures.
  • Adults with documented diagnosis and medical history consistent with guideline criteria.
  • Relevant exposure history consistent with COPD (e.g., smoking and/or biomass exposure).
  • On stable, guideline-based maintenance COPD therapy prior to randomization, per investigator judgment.
  • Protocol-defined exacerbation history, symptom burden, and lung function at screening.

Exclusion criteria

Exclusion Criteria:

  • Current or past asthma, or other respiratory disease that may confound assessment.
  • Clinically significant uncontrolled comorbidities that increase risk or interfere with participation/outcomes.
  • Immunodeficiency/immune dysregulation, active disease requiring systemic , or significant opportunistic infection history.
  • Active clinically significant infection or recent infection requiring systemic therapy; recent protocol-defined exacerbation.
  • Current/recent (except low-risk, adequately treated cancers per protocol) or clinically significant abnormal screening labs.
  • Prohibited recent vaccines or therapies, prior relevant biologic/targeted therapy exposure, severe to biologics/IMP, pregnancy/breastfeeding, or inability to comply (including substance abuse), per investigator judgment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
888 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo Injection, SC

    Other: Placebo

  • Experimental
    JKN2401 Injection

    JKN2401 Injection, SC dose A

    Biological: JKN2401 Injection

Interventions

  • BiologicalJKN2401 Injection

    JKN2401 subcutaneous injection, Q4W

  • OtherPlacebo

    Placebo subcutaneous injection,Q4W

06

What researchers measure

Primary outcomes

  1. Annualised rate of moderate or severe COPD exacerbations

    Time frame: during 52 weeks of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Sep 2027, 18 months later.

Of 109 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's planned 18 months is close to that.

Counting every sponsor, half of 142 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2025
First posted
Jan 9, 2026
StartEst.
Mar 2026
Primary completionEst.
Sep 2027
CompletionEst.
Nov 2027
Last update
Jan 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07330310
Responsible party
Sponsor
First posted
Jan 9, 2026
Start date
Mar 2026 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jan 14, 2026

Study contacts

Ying Yang
Contact
overseas@joincare.com
+86-0755-33268688

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion